Industry news that matters to you.  Learn more

Thinking Big by Thinking Small: PGXL Expands its Molecular Diagnostic Capability

Reading time: 2 – 4 minutes

PGXL Technologies has formed a strategic partnership with NX PharmaGen Inc. (NXPG) to support the identification of biomarkers using their NeXosomeTM microparticle enrichment technology. Exosomes and microparticles, which are found in bodily fluids, will aid diagnosis and treatment of cancer, immunological disorders, preterm birth, diseases of the central nervous system and other medical conditions.



Under this partnership, NXPG and PGXL Technologies are forming the PGXL NeXosomeTM Center of Excellence, whose mission is to provide access to advanced technologies that isolate and analyze exosomes and particles in bodily fluids. This center is the first of its kind to offer access to the NeXosomeTM enrichment platform and downstream assay development in a CLIA setting, with a mission to accelerate new discoveries into clinically useful applications.

“We’re providing an opportunity for researchers and pharmaceutical companies to increase their competencies in extracellular vesicle biology and to gain access to our methods of enrichment while simultaneously providing quality control in developing novel biomarkers of interest,” says Alan M. Ezrin, PhD, NXPG’s CEO. “We’re pleased to enter into this relationship with PGXL, as their competencies in a variety of molecular diagnostic techniques are quite complementary to our NeXosome platform.”

“NX PharmaGen has developed unique exosome-based tools,” says Dr. Roland Valdes, Jr., President of PGXL Laboratories. “As a CLIA-certified lab, PGXL is well-positioned to rapidly commercialize the NeXosome platform, making it available to researchers who wish to pursue their biomarker research with rigor, speed, precision and efficiency.”

Exosomes and microparticles are routinely shed from every cell in the body and can serve as rich sources of proteomic and genomic signals of tissue dysfunction. The information in these particles is extremely stable and the focus of intense interest in the scientific community, as exemplified by extensive NIH funding and ongoing research.

More than 3,000 studies have been published referencing exosomes and microparticles in an array of medical disciplines treating almost every part of the body and brain. The potential impact of the high-speed, high-accuracy NeXosome platform is virtually limitless.

“The PGXL NeXosome Center of Excellence brings PGXL a significant capability in the advancement of Personalized Medicine,” says Valdes. “We make it possible for researchers to look deeper and deeper into the molecular function of different illnesses and conditions. The more we understand about those deep functions, the better we can design treatments individualized for particular patients.”

The NeXosome platform complements PGXL’s existing single cell separation capability, which uses DEPArrayTM technology to isolate individual cells for analysis. Together, the NeXosome and DEPArray give PGXL Technologies a unique ability to detect cancer long before it appears on even the most discerning scans and imaging technology. PGXL makes both the single-cell DEPArray and the sub-cellular NeXosome platforms available to individuals and companies researching diagnostic techniques.

“We handle the isolation and enrichment of exosomic materials,” says Ezrin, “so researchers can spend their valuable time and dollars on the interpretation of their data. That’s where they’re going to have an impact.”     

Source: Business Wire